Who are Myobloc's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Nuceiva, Xeomin, Botox, Placebo / Botulinum Toxin A, Botulinum Toxin Type A 900kDa, Botulinum toxin A 150u.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/rimabotulinumtoxinb.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

Myobloc — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Myobloc (RIMABOTULINUMTOXINB) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Acetylcholine Release Inhibitor [EPC]. Area: Neuroscience.

marketed Acetylcholine Release Inhibitor [EPC] Neuroscience Recombinant protein Live · refreshed every 30 min

Target snapshot

Myobloc (RIMABOTULINUMTOXINB) — Elan Pharm. Myobloc works by blocking the release of acetylcholine, a chemical messenger that signals muscles to contract.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Myobloc TARGET	RIMABOTULINUMTOXINB	Elan Pharm	marketed	Acetylcholine Release Inhibitor [EPC]		2009-01-01
Nuceiva	BOTULINUM TOXIN TYPE A	GlaxoSmithKline K.K.	marketed	Acetylcholine Release Inhibitor [EPC]	Synaptosomal-associated protein 25	2019-01-01
Xeomin	INCOBOTULINUMTOXINA	Merz Pharms	marketed	Acetylcholine Release Inhibitor [EPC]		2015-01-01
Botox	ONABOTULINUMTOXINA	Allergan	marketed	Acetylcholine Release Inhibitor [EPC]	SNAP-25	2010-01-01
Placebo / Botulinum Toxin A	Placebo / Botulinum Toxin A	Walter Reed Army Medical Center	marketed	Neurotoxin / Acetylcholine release inhibitor	SNAP-25 (synaptosome-associated protein of 25 kDa)
Botulinum Toxin Type A 900kDa	Botulinum Toxin Type A 900kDa	Allergan	marketed	Neurotoxin; acetylcholine release inhibitor	SNAP-25 (synaptosome-associated protein of 25 kDa)
Botulinum toxin A 150u	Botulinum toxin A 150u	EvergreenHealth	marketed	Neurotoxin; Acetylcholine release inhibitor	SNARE proteins (specifically SNAP-25)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Acetylcholine Release Inhibitor [EPC] class)

BioActive Nutritional, Inc. · 2 drugs in this class
Cairo University · 1 drug in this class
Elan Pharm · 1 drug in this class
GlaxoSmithKline K.K. · 1 drug in this class
HUGEL INC · 1 drug in this class
Merz Pharms · 1 drug in this class
REVANCE THERAPEUTICS, INC. · 1 drug in this class
University Health Network, Toronto · 1 drug in this class
Allergan · 1 drug in this class
University of Oxford · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Myobloc — Competitive Intelligence Brief. https://druglandscape.com/ci/rimabotulinumtoxinb. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing